UPDATE : Friday, May 29, 2020
상단여백
Mediforum turned around to net profit in 2019
Mediforum, a pharmaceutical specialized in developing degenerative brain di...
by Shim Hyun-tai  |  2020-02-13 17:43
라인
Bukwang's dyskinesia treatment gets FDA nod for p 2 trials
The U.S. Food and Drug Administration has recently approved the phase 2 cli...
by Shim Hyun-tai  |  2020-02-13 14:22
라인
Dong-A ST posts robust profit in 2019
Dong-A ST said Thursday that it recorded sales of 612.2 billion won ($518.2...
by Lee Han-soo  |  2020-02-13 14:20
라인
ISU’s US partner releases clinical trial results of new hemophilia treatment
ISU Abxis, an orphan drug developer, said Wednesday that its U.S. partner, ...
by Shim Hyun-tai  |  2020-02-13 11:18
라인
SK Plasma to enter ME market with self-developed tech
SK Plasma has signed a memorandum of understanding with Arab Company for Dr...
by Shim Hyun-tai  |  2020-02-12 17:16
라인
Daewoong teams up with ADM Korea to develop new drugs
Daewoong Pharmaceutical said Wednesday that the company has signed a memora...
by Shim Hyun-tai  |  2020-02-12 15:58
라인
Bridge Biotherapeutics, Konkuk University to develop back-eye diseases treatment
Bridge Biotherapeutics has agreed with Konkuk University to introduce techn...
by Lee Han-soo  |  2020-02-12 14:49
라인
GC’s sales rose but profits fell in 2019
GC said Wednesday it recorded sales of 1.36 trillion won ($1.1 billion) las...
by Lee Han-soo  |  2020-02-12 11:40
라인
Medipost’s sales edge up, losses widen last year
Medipost said Wednesday that the company’s operating and net losses magnifi...
by Lee Han-soo  |  2020-02-12 11:40
라인
MSD Korea workers unhappy with spinoff plan
After MSD announced its “strategy” to separate some medicines under a new c...
by Kim Yun-mi  |  2020-02-11 14:57
라인
Fake news about new coronavirus drug candidate goes viral
Dubious reports are circulating in Korea claiming that a Chinese research i...
by Kim Yun-mi  |  2020-02-11 12:33
라인
Novartis' new drug for mutated lung cancer gets insurance coverage
A combined modality therapy of Rafinlar (ingredient: dabrafenib) and Meqsel...
by Kim Yun-mi  |  2020-02-10 18:29
라인
Hanmi Pharmaceutical renews yearly profit records
Hanmi Pharmaceutical said that it recorded 1.11 trillion won ($937 million)...
by Shim Hyun-tai  |  2020-02-10 12:29
라인
Court acquits Nature Cell president of stock manipulation
The Seoul Southern District Prosecutor Office Friday acquitted Nature Cell ...
by Jeong Sae-im  |  2020-02-07 18:40
라인
Handok’s medicine for childhood hypophosphatasia gets insurance benefits
Handok's Strensiq (ingredient: asfotase alfa), a medicine for childhood...
by Kim Eun-young  |  2020-02-07 15:59
라인
AstraZeneca Korea leaves umbrella trade union
AstraZeneca Korea’s branch of the Korea Democratic Pharmaceutical Union sai...
by Jeong Sae-im  |  2020-02-07 14:35
라인
Experts caution against hasty use of Olumiant for new coronavirus
Although a British artificial intelligence (AI) developer said Eli Lilly’s ...
by Kim Yun-mi  |  2020-02-06 16:08
라인
MSD to spin off women’s health, biosimilars under new firm
MSD said it would concentrate on oncology drugs and vaccines and establish ...
by Kim Yun-mi  |  2020-02-06 13:07
라인
Helixmith presents study results of neuropathic pain treatment
Helixmith unveiled the outcome of its study on developing a treatment for p...
by Shim Hyun-tai  |  2020-02-05 18:43
라인
‘Baricitinib emerges as potential treatment for new coronavirus’
Benevolent AI, a U.K.-based artificial intelligence (AI) healthcare firm, h...
by Lee Han-soo  |  2020-02-05 16:32
여백
여백
여백
Back to Top